附件: r - a 券等研究员莅临公司调研 080 注：从左起公司董事会秘书张斌、东方证券股份有限公司投资经理叶铮合影留念。 878711 8 注：从左起东方证券股份有限公司投资经理叶铮、公司董事会秘书张斌合影留念。 ...

Group 1: Company Overview - The company’s board secretary, Zhang Bin, is involved with several investment trust companies [1][3] - Collaborations include Yongfeng Securities Investment Trust Co., Taishin Securities Investment Trust Co., and others [1][3] Group 2: Research and Development - Zhang Bin participated in a group photo with researchers from various investment management firms [3]

附件： 注：前排右八为公司董事会秘书张斌与前海旗隆基金、东方资本、长城证券、粤信金融等机 构研究员合影留念。 注：前排右六为公司董事会秘书张斌与前海旗隆基金、东方资本、长城证券、粤信金融等机 构研究员合影留念。 ...

附件： 注：前排右三为公司董事会秘书张斌与国信证券、华商基金、上投摩根、万家基金等机构研 究员合影留念。 注：前排右五为公司董事会秘书张斌与国信证券、华商基金、上投摩根、万家基金等机构研 究员合影留念。 ...

附件： 注：从左起华润元大基金管理有限公司高级研究员张磊、公司董事会秘书张斌、元大宝来投 信投资一部专业经理张玉佩合影留念。 注：从左起元大宝来投信投资一部专业经理张玉佩、公司董事会秘书张斌、华润元大基金管 理有限公司高级研究员张磊合影留念。 ...

附件： 注：左起公司董事会秘书张斌、汇添富基金管理股份有限公司行业分析师张韡 、公司证券事 务代表曾宇婷合影留念。 注：左起公司证券事务代表曾宇婷、汇添富基金管理股份有限公司行业分析师张韡 、公司董 事会秘书张斌合影留念。 ...

Group 1: Company Overview - The company is called Da An Gene Co., Ltd., with the stock code 002030 [1] - The investor relations activity was conducted on November 18, 2015, at the company headquarters in Guangzhou [4] Group 2: Participants in the Investor Relations Activity - Participants included representatives from various investment firms, such as Shenzhen Qianhai Qilong Fund Management Co., Ltd. and China Orient Capital Research Institute [3][4] Group 3: Key Questions and Answers - PCR diagnostic reagents are included in the medical insurance coverage and are considered routine testing reagents [5] - The company aims to become a leading integrated supplier in China's diagnostic industry, with a focus on high-tech biopharmaceuticals [5] - The company’s PCR reagent products are primarily sold through direct sales, while other products use a combination of direct sales and agency models [6] - The company covers over 2,000 hospitals with its PCR diagnostic reagent products, with approximately 70% of these being tertiary hospitals [6] Group 4: Future Plans and Challenges - The company is in the early stages of hospital investment, with future plans dependent on development models and national policies [6] - There are considerations for expanding independent laboratories in collaboration with hospitals, reflecting changes in the independent laboratory development model [6] - The increase in operating costs outpacing revenue growth is attributed to the company's efforts in industry chain layout, which involves higher labor, research, and equipment costs [7]

附件： 注：左二为公司董事会秘书张斌与汇丰银行、霸菱资产、国泰康利资产研究员合影留念。 注：左三为公司董事会秘书张斌与汇丰银行、霸菱资产、国泰康利资产研究员合影留念。 ...

附件： 注：左四为公司董事会秘书张斌、右一为公司证券事务代表曾宇婷与南方基金、博时基金、 富国基金、国信证券等机构研究员合影留念。 注：左四为公司董事会秘书张斌、右二为公司证券事务代表曾宇婷与南方基金、博时基金、 富国基金、国信证券等机构研究员合影留念。 ...

Company Overview - The company, Daan Gene Co., Ltd., originated from Sun Yat-sen University and was established in 1991 as a technology development company [2][3] - The company transitioned from providing PCR technology services to developing qualitative PCR reagents [3] Historical Milestones - In 1999, the company received the first domestic new drug certificate for its hepatitis B virus nucleic acid (PCR) fluorescent detection kit, which was also the first commercialized diagnostic kit of its kind internationally [3] - The company underwent a share reform in 2000 and was listed on the Shenzhen Stock Exchange in 2004 [3] Laboratory Performance - The independent laboratory sector has experienced significant growth, maintaining an annual growth rate of over 30%, while the company's independent laboratory growth rate is approximately 38% [3] - The independent laboratory reached breakeven last year, with expectations to maintain growth at industry average levels in the coming years [3] Clientele - The primary clients of the independent laboratory are secondary hospitals and below [4] Technology Applications - Second-generation gene sequencing technology is applied in various fields, including tumor disease diagnosis, genetic disease testing, prenatal screening, and pharmacogenomics [4] Competitive Landscape - Domestic gene diagnostic technology is relatively strong in clinical applications, while foreign companies lead in research technology [4] Product Categories - The company's products are categorized into four main types: 1. Molecular diagnostic products primarily based on PCR 2. Immunological products based on the Elisa technology platform 3. Time-resolved products 4. Instrumentation products [4] Future Growth Focus - The company aims to focus on industrial layout and is investing in specialized companies along the industry chain through equity participation [4]